BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 22800881)

  • 1. Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis.
    Ma J; Liu Y; Huang XL; Zhang ZY; Myers JN; Neskey DM; Zhong LP
    Oral Oncol; 2012 Nov; 48(11):1076-84. PubMed ID: 22800881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy of cisplatin and fluorouracil regimen in head and neck squamous cell carcinoma: a meta-analysis.
    Su YX; Zheng JW; Zheng GS; Liao GQ; Zhang ZY
    Chin Med J (Engl); 2008 Oct; 121(19):1939-44. PubMed ID: 19080128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
    Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
    Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324.
    Sher DJ; Posner MR; Tishler RB; Sarlis NJ; Haddad RI; Holupka EJ; Devlin PM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e813-8. PubMed ID: 21300455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Results of definitive radiotherapy for squamous cell carcinomas of the larynx patients with subglottic extension].
    Lévy A; Blanchard P; Janot F; Temam S; Bourhis J; Daly-Schveitzer N; Tao Y
    Cancer Radiother; 2014 Jan; 18(1):1-6. PubMed ID: 24309002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
    Posner MR; Hershock DM; Blajman CR; Mickiewicz E; Winquist E; Gorbounova V; Tjulandin S; Shin DM; Cullen K; Ervin TJ; Murphy BA; Raez LE; Cohen RB; Spaulding M; Tishler RB; Roth B; Viroglio Rdel C; Venkatesan V; Romanov I; Agarwala S; Harter KW; Dugan M; Cmelak A; Markoe AM; Read PW; Steinbrenner L; Colevas AD; Norris CM; Haddad RI;
    N Engl J Med; 2007 Oct; 357(17):1705-15. PubMed ID: 17960013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.
    Cullen KJ; Schumaker L; Nikitakis N; Goloubeva O; Tan M; Sarlis NJ; Haddad RI; Posner MR
    J Clin Oncol; 2009 Dec; 27(36):6222-8. PubMed ID: 19917838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center.
    Athanasiadis I; Taylor S; Vokes EE; Pelzer HJ; Rademaker A; Mittal BB; Ganzenko N; Blough R; Lester EP; Kies MS
    Cancer; 1997 Feb; 79(3):588-94. PubMed ID: 9028372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
    Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
    Kim R; Hahn S; Shin J; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS
    Cancer Res Treat; 2016 Jul; 48(3):907-16. PubMed ID: 26582394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
    Karakaya E; Yetmen O; Oksuz DC; Dyker KE; Coyle C; Sen M; Prestwich RJ
    Oral Oncol; 2013 Jan; 49(1):55-9. PubMed ID: 22858313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemotherapy for head and neck cancer: recent data.
    Vokes EE
    Oncologist; 2010; 15 Suppl 3():3-7. PubMed ID: 21036882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC).
    Rivera F; Vega-Villegas ME; López-Brea M; Isla D; Mayorga M; Galdós P; Rubio A; Del Valle A; García-Reija F; García-Montesinos B; Rodríguez-Iglesias J; Mayordomo J; Rama J; Saiz-Bustillo R; Sanz-Ortiz J
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):253-61. PubMed ID: 17901953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck.
    Tsao AS; Garden AS; Kies MS; Morrison W; Feng L; Lee JJ; Khuri F; Zinner R; Myers J; Papadimitrakopoulou V; Lewin J; Clayman GL; Ang KK; Glisson BS
    J Clin Oncol; 2006 Sep; 24(25):4163-9. PubMed ID: 16943532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a meta-analysis.
    Ma J; Liu Y; Yang X; Zhang CP; Zhang ZY; Zhong LP
    World J Surg Oncol; 2013 Mar; 11():67. PubMed ID: 23497185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
    Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
    Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.
    Michiels S; Le Maître A; Buyse M; Burzykowski T; Maillard E; Bogaerts J; Vermorken JB; Budach W; Pajak TF; Ang KK; Bourhis J; Pignon JP;
    Lancet Oncol; 2009 Apr; 10(4):341-50. PubMed ID: 19246242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.
    Ock CY; Keam B; Kim TM; Han DH; Won TB; Lee SH; Hah JH; Kwon TK; Kim DW; Kim DY; Rhee CS; Wu HG; Sung MW; Heo DS
    Korean J Intern Med; 2016 May; 31(3):570-8. PubMed ID: 26976150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.